ADMA Biologics(ADMA) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for the full year 2025 was $510 million, representing a 20% year-over-year growth [5][14] - Adjusted EBITDA reached $231 million, increasing 40% year-over-year, while adjusted net income was $161 million, up 35% year-over-year [5][14] - Gross margin expanded to 57.4% from 51.5% in 2024, driven by Asceniv's growing contribution and yield-enhanced production [14] Business Line Data and Key Metrics Changes - Asceniv achieved $363 million in net revenue for 2025, reflecting a 51% year-over-year growth [7] - The company expects Asceniv to continue to grow, with a projected 70-30 revenue split between Asceniv and Bivigam in 2025 [30] - Fourth quarter 2025 adjusted EBITDA grew by 52% to $73.6 million, and adjusted net income increased by 57% to $52.6 million [15] Market Data and Key Metrics Changes - The company anticipates total revenue to exceed $635 million in 2026, with adjusted net income expected to exceed $255 million [16] - For 2027, total revenue is projected to exceed $775 million, and adjusted EBITDA is expected to exceed $455 million [16] Company Strategy and Development Direction - The company is focused on driving commercial execution, investing in a capital-efficient pipeline, and maintaining balance sheet discipline [11][12] - Strategic repositioning of the plasma collection network aims to enhance capital efficiency and secure long-term supply visibility [9][23] - The lead pipeline asset, SG-001, is viewed as a potential $300 million-$500 million peak annual revenue opportunity [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position entering 2026, highlighting strong demand in the U.S. IG market and improved earnings profile [17][22] - The integration of yield-enhanced production is expected to support meaningful gross margin growth and increasing earnings power [9][18] - Management noted that the company is well-positioned for sustained revenue growth and cash generation in the coming years [23] Other Important Information - The company announced a leadership transition with Terry Kohler appointed as the new CFO, succeeding Brad Tade [11][19] - The company ended 2025 with $88 million in cash, excluding proceeds from the plasma center divestiture [15] Q&A Session Summary Question: Update on Asceniv's role in product mix and revenue guidance - Management indicated a 70-30 split between Asceniv and Bivigam in 2025, expecting Asceniv's growth to continue [30] Question: Update on third-party supply contracts for RSV plasma - Management confirmed ongoing performance of third-party supply agreements and plans for expansion [34][36] Question: Expectations for receivables normalization and McKesson's impact - Management anticipates seeing McKesson's impact in the first half of the year, with normalization expected by mid to late 2026 [46][48]